Streamlined management of Peyronie’s disease
February 1, 2018
In this article, we describe our thought processes in treating patients with Peyronie's disease, which are summarized in an algorithm.
Sexual Function and Dysfunction
Progress on penile transplant moves forward
January 1, 2018
"[Penile transplantation] is a real advance for patients who have a penile deficiency or penile loss," says Arthur L. Burnett, II, MD, MBA.
Penile transplant guidelines missing in action
January 1, 2018
There are no national or international guidelines regarding penile transplants, raising a question without a concrete answer: What are the rules and the limits?
Survey: Urologists lack knowledge, training in transgender care
November 20, 2017
While urologists are generally comfortable discussing patients’ sexual orientation, they report that both their knowledge of care of transgender patients and training in such care are lacking.
Shock waves may change future of ED therapy
November 17, 2017
It’s hard to argue against an erectile dysfunction treatment that is potentially disease modifying, is noninvasive, and seems to do no harm. The treatment, low-intensity shock wave therapy, has yet to earn the FDA’s approval but is widely used in other countries. Early results from ongoing U.S. trials are promising.
New Products: FDA approves treatment for complicated UTI
October 11, 2017
Other products and services discussed in this round-up include a biosimilar for cancer, an American College of Surgeons manual on quality initiatives, a kidney cancer microsite, and more.
Uro Pipeline: Supplemental application submitted for advanced RCC treatment
August 15, 2017
Other pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.
New products: Holmium laser increases stone ablation volume
July 14, 2017
Other products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more
Uro Pipeline: Phase IIb study begins for intraprostatic localized PCa drug
June 27, 2017
Other pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.
